Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 2 (2005), Issue 3 (March)

1. Activation of p38 and N-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascades is required for induction of apoptosis in Parkinson's disease cybrids.
   Mol Cell Neurosci, 28(3): 452-61. [Abstract] [Full-text]
2. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
   Pharmacol Ther, 105(3): 267-310. [Abstract] [Full-text]
3. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease.
   J Mass Spectrom, 40(2): 261-70. [Abstract] [Full-text]
4. Temporal evolution of oscillations and synchrony in GPi/muscle pairs in Parkinson's disease.
   J Neurophysiol, 93(3): 1569-84. [Abstract] [Full-text]
5. Increased norepinephrine-associated adrenomedullary inclusions in Parkinson's disease.
   Pathol Int, 55(3): 130-6. [Abstract] [Full-text]
6. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.
   Am J Hum Genet, 76(4): 672-80. [Abstract] [Full-text]
7. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
   Brain Res, 1038(1): 83-91. [Abstract] [Full-text]
8. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
   Brain Res, 1038(1): 1-10. [Abstract] [Full-text]
9. Acoustic analysis of clear versus conversational speech in individuals with Parkinson disease.
   J Commun Disord, 38(3): 215-30. [Abstract] [Full-text]
10. The effects of levodopa on word intelligibility in Parkinson's disease.
    J Commun Disord, 38(3): 187-96. [Abstract] [Full-text]
11. Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients.
    Ann Neurol, 57(3): 448-52. [Abstract] [Full-text]
12. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.
    Ann Neurol, 57(3): 439-43. [Abstract] [Full-text]
13. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
    Ann Neurol, 57(3): 453-6. [Abstract] [Full-text]
14. Familial Parkinson's disease: clinical and genetic analysis of four Basque families.
    Ann Neurol, 57(3): 365-72. [Abstract] [Full-text]
15. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
    Neurobiol Dis, 18(3): 492-8. [Abstract] [Full-text]
16. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Hum Gene Ther, 16(2): 262-70. [Abstract] [Full-text]
17. Gene dosage and pathogenesis of Parkinson's disease.
    Trends Mol Med, 11(3): 91-6. [Abstract] [Full-text]
18. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Clin Ther, 27(1): 58-63. [Abstract] [Full-text]
19. Contribution of aging to the severity of different motor signs in Parkinson disease.
    Arch Neurol, 62(3): 467-72. [Abstract] [Full-text]
20. Effect of MDR1 haplotype on risk of Parkinson disease.
    Arch Neurol, 62(3): 460-4. [Abstract] [Full-text]
21. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
    Arch Neurol, 62(3): 378-82. [Abstract] [Full-text]
22. Molecular pathogenesis of Parkinson disease.
    Arch Neurol, 62(3): 353-7. [Abstract] [Full-text]
23. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Lancet, 365(9463): 947-54. [Abstract] [Full-text]
24. Fear recognition is impaired by subthalamic nucleus stimulation in Parkinson's disease.
    Neuropsychologia, 43(7): 1054-9. [Abstract] [Full-text]
25. Activation of conflicting responses in Parkinson's disease: evidence for degrading and facilitating effects on response time.
    Neuropsychologia, 43(7): 1033-43. [Abstract] [Full-text]
26. Information-integration category learning in patients with striatal dysfunction.
    Neuropsychology, 19(2): 212-22. [Abstract] [Full-text]
27. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).
    Pharmacogenomics J, 5(2): 135-41. [Abstract] [Full-text]
28. The effect of subthalamic nucleus stimulation on kinaesthesia in Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 76(4): 569-71. [Abstract] [Full-text]
29. Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial.
    J Neurol Neurosurg Psychiatry, 76(4): 491-7. [Abstract] [Full-text]
30. Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease.
    J Neurochem, 93(1): 246-56. [Abstract] [Full-text]
31. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases.
    J Biol Chem, 280(12): 11648-55. [Abstract] [Full-text]
32. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
    Neuroimmunomodulation, 12(2): 81-4. [Abstract] [Full-text]
33. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Prog Neurobiol, 75(2): 109-24. [Abstract] [Full-text]
34. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease.
    Proc Natl Acad Sci U S A, 102(12): 4294-9. [Abstract] [Full-text]
35. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
    J Neural Transm, 112(4): 519-37. [Abstract] [Full-text]
36. Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease.
    J Neural Transm, 112(4): 499-518. [Abstract] [Full-text]
37. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease.
    Am J Med Genet B Neuropsychiatr Genet, 134(1): 93-103. [Abstract] [Full-text]
38. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.
    Eur J Nucl Med Mol Imaging, 32(3): 302-7. [Abstract] [Full-text]
39. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Brain Res Mol Brain Res, 134(1): 155-61. [Abstract] [Full-text]
40. Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.
    Brain Res Mol Brain Res, 134(1): 67-75. [Abstract] [Full-text]
41. The MPTP model of Parkinson's disease.
    Brain Res Mol Brain Res, 134(1): 57-66. [Abstract] [Full-text]
42. Stem cells may reshape the prospect of Parkinson's disease therapy.
    Brain Res Mol Brain Res, 134(1): 34-51. [Abstract] [Full-text]
43. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.
    Brain Res Mol Brain Res, 134(1): 24-33. [Abstract] [Full-text]
44. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Brain Res Mol Brain Res, 134(1): 18-23. [Abstract] [Full-text]
45. The speed of sit-to-stand can be modulated in Parkinson's disease.
    Clin Neurophysiol, 116(4): 780-9. [Abstract] [Full-text]
46. Paradoxical modulation of tendon tap reflex during voluntary contraction in Parkinson's disease.
    Clin Neurophysiol, 116(4): 769-74. [Abstract] [Full-text]
47. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    J Neurol Sci, 231(1): 35-9. [Abstract] [Full-text]
48. Developmental pesticide exposures and the Parkinson's disease phenotype.
    Birth Defects Res A Clin Mol Teratol, 73(3): 136-9. [Abstract] [Full-text]
49. Analysis of the course of Parkinson's disease under dopaminergic therapy: performance of "fast tapping" is not a suitable parameter.
    Mov Disord, 20(3): 348-54. [Abstract] [Full-text]
50. Disparities in the recording of Parkinson's disease on death certificates.
    Mov Disord, 20(3): 315-21. [Abstract] [Full-text]
51. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
    Mov Disord, 20(3): 363-6. [Abstract] [Full-text]
52. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Mov Disord, 20(3): 342-4. [Abstract] [Full-text]
53. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
    Mov Disord, 20(3): 271-82. [Abstract] [Full-text]
54. Analysis of the glucocerebrosidase gene in Parkinson's disease.
    Mov Disord, 20(3): 367-70. [Abstract] [Full-text]
55. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.
    Mov Disord, 20(3): 383-5. [Abstract] [Full-text]
56. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats.
    Behav Brain Res, 159(1): 153-61. [Abstract] [Full-text]
57. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD.
    Ann Neurol, 57(4): 564-7. [Abstract] [Full-text]
58. Multiple regions of alpha-synuclein are associated with Parkinson's disease.
    Ann Neurol, 57(4): 535-41. [Abstract] [Full-text]
59. Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of alpha-Synuclein in Drosophila.
    Genesis, 41(4): 154-9. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.